About OraVerse OraVerse
is a breakthrough that reverses unwanted lingering numbness after routine dental procedures where a local anesthetic containing a vasoconstrictor was used.
11) Pediatric dentist David Chin, DDS (electronic communication with the author, April 2010), who has been compensated by Novalar Pharmaceuticals to host continuing education courses regarding OraVerse
, said, "Most of the parents of patients are appreciative of the action of Oraverse
when I ask at the next appointment.
OraVerse is indicated for reversal of the soft-tissue anesthesia, i.
In clinical trials, the most common adverse events with OraVerse (phentolamine mesylate) vs.
Expansion of OraVerse into Europe represents a significant near-term opportunity for Novalar, and it is our goal to obtain marketing approval by mid-2011," said Donna Janson, President and Chief Executive Officer of Novalar.
The proposed indication for OraVerse in Europe is comparable to the product's approved indication in the United States.
Systems has established itself as a leader in the field of tissue regeneration, dental implantology and new dental technologies, which makes it the perfect partner to launch OraVerse into Israel.
We also have the necessary infrastructure and existing relationships within the local dental community for the successful launch of OraVerse in Israel and we look forward to offering this unique product to our customers," said Fanny Gross, President and Chief Executive Officer of H.
Participating dentists were provided with 10 cartridges of OraVerse and a survey to provide to their patients to record their experience with the product.
86% reported that OraVerse improved their dental experience
We are eager to add OraVerse
to our portfolio of product offerings, which includes our market-leading local anesthetic Ultracain," said Peter Guenter, General Manager Commercial Operations at Sanofi-Aventis Deutschland.
is the first and only local anesthesia reversal agent that accelerates the return to normal sensation and function for patients who want to avoid the unwanted and unnecessary lingering soft tissue anesthesia following routine dental procedures.
The primary market segments for OraVerse
will be general dental practitioner and pediatric dentist's offices throughout the U.
a dental specialty pharmaceutical company, announced the publication of three clinical trials on the use of OraVerse
(phentolamine mesylate) injection as a local dental anesthetic reversal agent in the August 2008 issue of the Journal of the American Dental Association (JADA).
is the first pharmaceutical agent indicated for the reversal of soft-tissue anesthesia and the associated functional deficits resulting from a local dental anesthetic.